Coherus BioSciences (CHRS) Reports Q2 Loss of $1.56
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Coherus BioSciences Reports Second Quarter 2015 Financial and Operating Results
August 10, 2015 4:02 PM EDTREDWOOD CITY, Calif., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today reported financial results and reviewed corporate events for the second quarter ended June 30, 2015.
Highlights include:
CHS-1701 (pegfilgrastim (Neulasta®) biosimilar): In May 2015, Coherus completed the enrollment of its pivotal pharmacokinetic (PK) and pharmacodynamic (PD) study, which, if positive, could support the filing of a 351(k) biologics license application (BLA). An additional immunogenicity study is underway in healthy volunteers pursuant to this BLA and is projected to conclude... MoreCoherus BioSciences Reports Second Quarter 2015 Financial and Operating Results
August 10, 2015 4:02 PM EDTREDWOOD CITY, Calif., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today reported financial results and reviewed corporate events for the second quarter ended June 30, 2015.
Highlights include:
CHS-1701 (pegfilgrastim (Neulasta®) biosimilar): In May 2015, Coherus completed the enrollment of its pivotal pharmacokinetic (PK) and pharmacodynamic (PD) study, which, if positive, could support the filing of a 351(k) biologics license application (BLA). An additional immunogenicity study is underway in healthy volunteers pursuant to this BLA and is projected to conclude... More